Research-grade media leads with 34% share while liquid formats account for 43% as producers prioritize reproducible cell growth and traceable inputs

ROCKVILLE, Md., September 15, 2026 — Cultivated-cell developers are placing greater emphasis on media qualification as food-grade inputs, serum-free formulations, and documented manufacturing controls become more important during the transition from laboratory research to pilot production. In May 2026, the U.S. Food and Drug Administration issued final guidance on chemistry, manufacturing, and controls flexibilities for human cellular and gene therapy products, reinforcing the broader importance of controlled manufacturing inputs and documentation in cell-based development.

Against this backdrop, Fact.MR estimates that the Cultivated Media Grades Market will reach USD 620.0 million in 2026, up from USD 508.2 million in 2025. Demand is projected to climb to USD 4.53 billion by 2036, reflecting a 22.0% CAGR and an absolute dollar opportunity of USD 3.91 billion.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=16213

Why Are Cultivated Media Grades Becoming a Strategic Input?

Cultivated media grades are moving from a laboratory supply consideration toward a process-development decision. Cell-based food producers, research institutes, CDMOs, and cell-therapy researchers require formulations that deliver reproducible cell growth while providing sufficient documentation around ingredient origin, composition, and batch consistency.

For cultivated meat companies, the media decision also has direct implications for production economics. Growth factors, amino acids, supplements, and other inputs can substantially affect the cost of expanding cells at pilot and commercial scale.

A formulation that performs well in a small research vessel may not automatically deliver identical results during scale-up. Suppliers therefore face increasing pressure to demonstrate performance across cell lines, production stages, and larger culture systems.

Research Grade Holds 34% Share

Research-grade media is expected to account for 34.0% of the Grade segment in 2026, making it the leading category.

Research-grade formulations are widely used during early cell-line screening and formulation development. Researchers need flexibility while testing different cell types, growth conditions, and nutrient combinations before committing to a production formulation.

Food-grade and serum-free media become increasingly relevant as developers move toward pilot production and regulatory review. At this stage, suppliers must provide greater clarity around input origin, formulation consistency, and manufacturing controls.

The progression from research grade to production-oriented media creates an important commercial pathway for suppliers. Early formulation performance can influence which media provider remains part of a customer's later-stage development program.

Liquid Media Leads With 43% Share

Liquid media is projected to hold 43.0% of the Format segment in 2026.

Ready-to-use liquid formulations reduce preparation steps and can minimize weighing and mixing errors during laboratory and pilot operations. This makes liquid media particularly attractive where researchers frequently modify experimental conditions.

Powder and concentrate formats remain relevant for customers seeking lower shipping volumes, extended storage options, or greater control over final formulation. Custom kits can also serve species-specific and cell-line-specific requirements.

The format decision ultimately depends on the balance between convenience, storage, logistics, cost, and formulation flexibility.

Cell Growth Accounts for 37% of Functional Demand

Cell growth is forecast to represent 37.0% of the Function segment in 2026, making it the leading functional application.

Viable cell expansion is the first performance test for cultivated media. Producers compare doubling time, passage consistency, cell viability, and overall yield before evaluating differentiation or recovery characteristics.

Performance data can become a major differentiator between suppliers. In July 2025, Multus Biotechnology reported that its Proliferum B media maintained 15–25-hour doubling times in bovine fibroblasts while demonstrating performance across bovine fibroblast and satellite-cell lines. Such benchmarks give developers a measurable reference when evaluating animal-component-free formulations.

Cultivated Meat Leads Application Demand

Cultivated meat is estimated to account for 39.0% of the Application segment in 2026.

The category requires repeated media use across cell banking, expansion, differentiation, and pilot-scale production. Consequently, media represents both a biological input and a significant process-cost consideration.

Producers are increasingly separating early discovery formulations from production-oriented food-grade media. This approach can reduce the risk of discovering formulation or documentation problems after a process has already advanced toward scale-up.

Precision fermentation, cell-therapy research, and bioprocess development provide additional demand opportunities for media suppliers with broader formulation and documentation capabilities.

Producers Represent 41% of Customers

Producers are forecast to account for 41.0% of the Customer segment in 2026.

Cultivated-food producers purchase media repeatedly during cell-line development, formulation testing, cell-bank preparation, and pilot runs. Their procurement decisions depend on biological performance as well as cost, availability, documentation, and supplier consistency.

Research institutes remain important early-stage customers. CDMOs can influence supplier selection by transferring media specifications across multiple customer projects, while ingredient suppliers participate in the value chain through specialized components and formulations.

What Is Driving Cultivated Media Grades Market Growth?

Food-grade media qualification is a major market driver. As cultivated meat developers approach formal regulatory review, documented production inputs become more important.

The transition toward serum-free and animal-component-free formulations is another structural driver. Defined formulations can reduce biological variability and provide greater traceability around production inputs.

Scale-up is equally important. Larger bioreactors expose the economic impact of expensive growth factors and other media components, encouraging developers to optimize formulations before commercial production.

Cell-therapy and bioprocess development provide an additional demand base. Developers in these fields require controlled media inputs and detailed manufacturing records when formulation changes could affect product quality.

Fact.MR estimates that food-grade media qualification, serum-free transition, pilot-scale expansion, and cell-therapy documentation will remain important contributors to market growth through 2036.

Growth-Factor Costs and Batch Comparability Remain Challenges

High-cost recombinant growth factors remain a significant restraint. Expensive media components can increase the cost of cultivated biomass and make commercial-scale production economics more difficult.

Regulatory review of media components also adds complexity. Producers need supplier documentation that clearly identifies input origin, composition, and manufacturing controls.

Batch comparability presents another challenge. A media formulation that performs consistently in a laboratory vessel may behave differently during larger-scale production, creating additional validation requirements.

For suppliers, repeatability is therefore becoming as important as headline growth performance.

United States Leads Growth at 24.2% CAGR

The United States is projected to record a 24.2% CAGR from 2026 to 2036, making it the fastest-growing country in the Fact.MR analysis.

The U.S. market benefits from cultivated-food development as well as its established cell-therapy and bioprocess research infrastructure. Formal food consultation activity is increasing the importance of documented production inputs.

Germany follows with a 23.1% CAGR, supported by its gene and cell therapy infrastructure. Japan is projected to grow at 21.6%, reflecting its strong iPS-cell research ecosystem and regenerative-medicine programs.

France is forecast to expand at 20.7% CAGR, while Brazil is projected to record 19.8% CAGR as cultivated-meat research and local cell-culture capabilities develop.

What Is the Competitive Landscape?

The competitive environment includes established cell-culture suppliers alongside specialized companies developing media for cellular agriculture.

Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Ajinomoto, and Multus Biotechnology are among the key companies profiled by Fact.MR.

Thermo Fisher Scientific brings broad cell-culture media capabilities through its Gibco portfolio. Merck KGaA participates through cell-culture and bioprocess solutions, while Sartorius has expanded production infrastructure supporting cell and gene therapy inputs.

Ajinomoto is developing media technology for cultivated-meat applications, while Multus Biotechnology focuses on animal-component-free formulations for cellular agriculture.

Shambhu Nath Jha, Principal Consultant at Fact.MR, said, “Media qualification is becoming the commercial bottleneck in cultivated cell production. Producers are expected to compare media grades by growth rate, input origin and documentation quality before committing to scale-up. Suppliers that combine animal-component-free formulations, clean regulatory files and repeatable performance data have a clearer route into long-term supply programs.”

Market Snapshot

2025 Market Value: USD 508.2 million
2026 Market Value: USD 620.0 million
2036 Forecast Value: USD 4.529 billion
CAGR, 2026–2036: 22.0%
Absolute Dollar Opportunity: USD 3.909 billion
Leading Grade: Research Grade, 34.0%
Leading Format: Liquid, 43.0%
Leading Function: Cell Growth, 37.0%
Leading Application: Cultivated Meat, 39.0%
Leading Customer: Producers, 41.0%
Fastest-Growing Country: United States, 24.2% CAGR
Key Companies: Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Ajinomoto, Multus Biotechnology
Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/cultivated-media-grades-market

Report Scope and Methodology

Fact.MR's Cultivated Media Grades Market study analyzes the industry by Grade, Format, Function, Application, Customer, and Region.

The report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with detailed country analysis for the United States, Germany, Japan, France, and Brazil.

The research draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews. The analysis combines primary interviews with media suppliers, cultivated-meat developers, bioprocess teams, CDMOs, and research users with desk research covering regulatory publications, government data, company announcements, technical studies, and product information.

The study uses a hybrid top-down and bottom-up approach, incorporating media-grade adoption, cultivated-meat pipelines, bioprocess demand, country activity, and provider portfolio analysis.

Explore More Related Studies Published by Fact.MR Research:

Precision Flavor Enzymes Market- https://www.factmr.com/report/precision-flavor-enzymes-market

Functional Soda Fibers Market- https://www.factmr.com/report/functional-soda-fibers-market

Umami Flavor Enhancers Market- https://www.factmr.com/report/umami-flavor-enhancers-market

Functional Fonio Grains Market- https://www.factmr.com/report/functional-fonio-grains-market

Gummy Texture Stabilizers Market- https://www.factmr.com/report/gummy-texture-stabilizers-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, an independent market research and consulting firm providing syndicated research, custom research, and strategic consulting across healthcare, technology, food and beverage, chemicals and materials, industrial goods, consumer goods, and other major industries.

Fact.MR serves clients globally through offices in Rockville, Maryland, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Dublin Office:
Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.